Nymox Pharma (NASDAQ: NYMX) Nymox Pharma looked like it was going to have a rough day today in the opening minutes. However, after about 3 minutes in the red, the stock started spiking. Now, it’s well into the green. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching with regard to … Read more
Nymox Pharma (NASDAQ: NYMX) Nymox Pharma is having an incredible time in the market today, and for good reason. The company released new study results from Phase 3 clinical trials surrounding their lead candidate. Today, we’ll talk about the results, what we saw from the stock as a result, and what we can expect to … Read more
Nymox Pharma (NASDAQ: NYMX) Nymox Pharma is having an incredible day in the market today, and for good reason. Yesterday, the company reported the results from a key phase 3 clinical trial. Today, we’ll talk about the results that were released, how the market reacted to the news, and what we can expect to see … Read more
Nymox Pharma (NASDAQ: NYMX) Nymox Pharma is having an incredibly strong day in the market today. It’s a much needed turn from the drastic declines we saw earlier this week. So, what’s sending the stock upward? Well, the company has announced major progress with regard to fexapotide. Today, we’ll talk about that data, how the … Read more
Nymox Pharma (NASDAQ: NYMX) While the global market is in the midst of a tailspin, there are a few stocks that are doing incredibly well. One of them happens to be Nymox Pharma. Today, the company is continuing the upward movement that we’ve seen since last Monday. Considering the reason for the gains, we’re likely … Read more
Nymox Pharma (NASDAQ: NYMX) Nymox Pharma is having an incredibly strong day in the market today, and for good reason. The company announced data from 7-year prospective studies. The data was overwhelmingly positive. Today, we’ll talk about the data that was released, how the market reacted to the news, and what we can expect to … Read more
Gilead Sciences Climbs On Positive Earnings Gilead Sciences, Inc. (NASDAQ: GILD) Gilead Sciences seems to be today’s biggest story in the healthcare space. While several investors were concerned about the company’s ability to continue to produce earnings growth, those concerns were put to rest last night when the company’s earnings report for the quarter was … Read more
Pfizer Gains On Positive Earnings & Updated Guidance Pfizer (NYSE: PFE) Pfizer released their earnings report for the second quarter today. The report was overwhelmingly positive. While PFE did miss top-line expectations, when it comes to earnings, they beat analyst expectations by $0.04 per share. As a matter of fact, the quarter’s performance was so … Read more